Cover image of the article: Effect of potassium channel blocker 4-aminopyridine pretreatment on the 6-OHDA-induced Parkinson's disease in rats

Image Credit:J Inflamm Dis

Effect of potassium channel blocker 4-aminopyridine pretreatment on the 6-OHDA-induced Parkinson's disease in rats

Authors

M Sofiabadi,*, hashem haghdoost-yazdi, M Mahmudi, H Pri, T Dargahi, M Yaghubidust
*Corresponding Author: Email: msofiabadi@mail.com

Journal of Inflammatory Diseases:Vol. 19, issue 2; 11-20
Published online:Jul 22, 2015
Article type:Research Article
How to Cite:Sofiabadi M, haghdoost-yazdi H, Mahmudi M, Pri H, Dargahi T, et al. Effect of potassium channel blocker 4-aminopyridine pretreatment on the 6-OHDA-induced Parkinson's disease in rats. J Inflamm Dis. 2024;19(2):e155895. doi:

Abstract

  Background: Nuclease and caspase enzymes activities which promote death signals and lead to apoptosis are dependent to potassium ions.   Objective: The aim of this study was to determine the effect of 4-aminopyridine (4-AP) potassium channel blocker on the animal model of Parkinson's disease.   Methods: This experimental study was performed in Qazvin University of Medical Sciences, 2013. Male Rats were received different doses of 4-AP twice daily from half an hour before injection of 6-hydroxydopamine (6-OHDA) to 7 or 15 days after that. 6-OHDA was injected into medial forebrain bundle (MFB) in acute model groups and into striatum in chronic model groups. The severity of Parkinsonism was assessed by standard behavioral methods. Data were analyzed using Kruskal-Wallis and Mann Whitney U tests.   Findings: In acute model groups, administration of 0.5 mg/kg 4-AP (n=9) had no remarkable effect on behavioral symptoms, but 1 mg/kg 4-AP (n=8) significantly reduced the severity of apomorphine-induced rotations and improved motor learning in rotarod test. In chronic model groups, although 1 mg/kg 4-AP (n=7) significantly reduced the severity of rotations and improved motor learning, but 0.5 mg/kg 4-AP (n=8) was more effective.   Conclusion: Pretreatment with 4-AP can reduce 6-OHDA-induced dopaminergic neuron death. Since the chronic model of 6-OHDA is more similar to Parkinson's disease in human, the low dose of 4-AP is recommended for treatment of this disease.     Keywords: Parkinson Disease , Potassium Channel Blockers , Oxidopamine , Substantia Nigra   Citation: Sofiabadi M, Haghdoost-Yazdi H, Mahmudi M, Piri H, Dargahi T, Yaghubidust M. Effect of potassium channel blocker 4-aminopyridine pretreatment on the 6-OHDA-induced Parkinson's disease in rats. J Qazvin Univ Med Sci. 2015 19 (2): 11-20.

Highlights

Copyright

© 2024, Journal of Inflammatory Diseases. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

13
Jul
2016
Effect of potassium channel blocker  of Tetraethylammonium pretreatment on prevention of the 6-OHDA-induced chronic Parkinson\'s disease in rats

Effect of potassium channel blocker of Tetraethylammonium pretreatment on prevention of the 6-OHDA-induced chronic Parkinson\'s disease in rats

Hashem Haghdoost-Yazdi,
Soheila sehat bakhsh,
Mohammad Sofiabadi,
Tahereh Dargahi,
MH Yaghubidust,
Hossein Piri

Haghdoost-Yazdi H, sehat bakhsh S, Sofiabadi M, Dargahi T, Yaghubidust M, et al. Effect of potassium channel blocker of Tetraethylammonium pretreatment on prevention of the 6-OHDA-induced chronic Parkinson\'s disease in rats. J Inflamm Dis. 2024;20(2):e155962. doi:

28
Sep
2014
Comparison the protective effects of aqueous extract of Iranian propolis in 6-hydroxydopamine-induced model of parkinsonism in male rat with L-DOPA: A behavioral and histological evaluation

Comparison the protective effects of aqueous extract of Iranian propolis in 6-hydroxydopamine-induced model of parkinsonism in male rat with L-DOPA: A behavioral and histological evaluation

Manoochehr Safari,
badban badban,
Hamid Reza Sameni,
Ahmad Reza Bandegi,
ali rashidypour,
Abbas Ali Vafaei

Safari M, badban B, Sameni HR, Bandegi AR, rashidypour A, et al. Comparison the protective effects of aqueous extract of Iranian propolis in 6-hydroxydopamine-induced model of parkinsonism in male rat with L-DOPA: A behavioral and histological evaluation. koomesh. 2014;15(4):e152895. doi:

31
Dec
2023
Effect of Rilmenidine on Substantia Nigra Neurons Injury in a Rat Model of Parkinson's Disease

Effect of Rilmenidine on Substantia Nigra Neurons Injury in a Rat Model of Parkinson's Disease

Hadi Keshavarzi,
Shahram Darabi,
Zahra Zia,
Fatemeh Sabbaghziarani

Keshavarzi H, Darabi S, Zia Z, Sabbaghziarani F. Effect of Rilmenidine on Substantia Nigra Neurons Injury in a Rat Model of Parkinson's Disease. J Inflamm Dis. 2023;27(3):e150909. doi: https://doi.org/10.69107/jid-150909

12
Aug
2025
Behavioral Outcomes and Histopathological Alterations in a Rotenone-induced Parkinson’s Disease Model: A Comparative Study of L-Dopa and Apomorphine

Behavioral Outcomes and Histopathological Alterations in a Rotenone-induced Parkinson’s Disease Model: A Comparative Study of L-Dopa and Apomorphine

Sayed Mostafa Modarres Mousavi,
Fatemeh Alipour,
Shima Lotfollahzadeh,
Faezeh Mousazadeh,
Hasan Hosseini,
Saman Hosseinkhani
,et al.

Modarres Mousavi SM, Alipour F, Lotfollahzadeh S, Mousazadeh F, Hosseini H, et al. Behavioral Outcomes and Histopathological Alterations in a Rotenone-induced Parkinson’s Disease Model: A Comparative Study of L-Dopa and Apomorphine. J Rep Pharm Sci. 2025;13(1):e162472. doi: https://doi.org/10.5812/jrps-162472

26
Apr
2016
Effects of Isradipine on Induced-Parkinson’s Disease in Rats

Effects of Isradipine on Induced-Parkinson’s Disease in Rats

Gholamreza Komeili,
Farzaneh Farajian-Mashhadi

Komeili G, Farajian-Mashhadi F. Effects of Isradipine on Induced-Parkinson’s Disease in Rats. Zahedan J Res Med Sci. 2016;18(4):e6444. doi: https://doi.org/10.17795/zjrms-6444

More by these authors

M SofiabadiPubMedScholar
hashem haghdoost-yazdiPubMedScholar
M MahmudiPubMedScholar
T DargahiPubMedScholar
M YaghubidustPubMedScholar
Share
Cited by
Metrics